Drug intelligence / Profile preview

7-deazaguanine

Development stage
Unknown
Modality
Small Molecules
01

Overview

**7-Deazaguanine** is a synthetic analog of guanine in which the nitrogen at position seven of the purine ring is replaced by a carbon atom. It belongs to the class of pyrrolopyrimidines and has been studied primarily as an experimental compound. In biological systems—particularly in certain bacteria and bacteriophages—derivatives of 7-deazaguanine are incorporated into DNA or RNA as modified nucleobases. These modifications can play roles in protecting genetic material from restriction enzymes (antirestriction systems), serving as epigenetic marks, or providing resistance to environmental stressors such as radiation. Recent research has identified that some derivatives act through diverse mechanisms including inhibition of protein kinases (such as DYRK1A) and interference with cellular processes associated with adenine nucleosides. For example, some deazapurines related to this scaffold have shown cytotoxicity via protein kinase C inhibition or cyclin-dependent kinase inhibition; however, these effects are more established for closely related compounds rather than for unmodified 7-deazaguanine itself. In laboratory settings, it is used mainly for biochemical research purposes—including studies on DNA modification and enzyme substrate specificity—and not approved for clinical use in humans.[1][4][8]

Other names
2-amino-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one2-amino-7H-pyrrolo[2,3-d]pyrimidin-4-ol2-amino-4-hydroxypyrrolo[2,3-d]pyrimidine2-amino-3H-pyrrolo[2,3-d]pyrimidin-4(7H)-oneUNII-GPL8T5ZO3MUNII-GPL-8T5ZO3MUNII-GPL 8T5ZO3MGPL8T5ZO3MGPL-8T5ZO3MGPL 8T5ZO3M2-amino-1H-pyrrolo[2,3-d]pyrimidin-4(7H)-one
02

Targets

DYRK1A (Dual-specificity tyrosine-phosphorylation-regulated kinase 1A)

Beyond the preview

Go deeper on 7-deazaguanine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 7-deazaguanine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call